5-Amino-1MQ 50mg Capsules (60ct)
$119.00
Subscribe Monthly & Save! Email us Here to get started
Create a free account to unlock ordering and complete your purchase.
Description
5-Amino-1MQ 50mg Capsules (60ct) | Laboratory Research Compound | Mile High Peptides LLC
Commonly Researched For:
-
Cellular fat metabolism and body composition
-
NAD+/NNMT-related metabolic pathways
-
Cellular energy, performance, and healthy aging models
Description
5-Amino-1MQ is a small-molecule research compound that targets the NNMT (nicotinamide N‑methyltransferase) enzyme, a key player in how cells handle nicotinamide and NAD+ metabolism. Labs often choose this material when they want to explore fat metabolism and cellular energy from the “inside out,” at the enzyme and mitochondrial level rather than just at the surface.
Researchers commonly use 5-Amino-1MQ in models focused on fat mass, metabolic rate, and energy production to see how NNMT inhibition may influence NAD+ availability and mitochondrial function. It frequently appears in studies interested in body composition, performance, and longevity-related pathways, where the goal is to understand how supporting cellular energy systems might impact overall metabolic health.
Mile High Peptides LLC supplies this compound for research and educational purposes.
Product Details
- Total compound per capsule: 50mg
- 60 capsules per bottle
- Laboratory research use only
- Intended for analytical and in-vitro research applications
Important Notice
- For laboratory research and educational purposes only
- Not for human consumption
- Not for medical, cosmetic, or therapeutic use
- Not intended to diagnose, treat, cure, or prevent any disease
- Observations and research outcomes may vary based on handling, storage, environment, methodology, and study conditions
- Materials supplied are not finished consumer products
Mile High Peptides LLC supplies materials strictly for in-vitro laboratory research and analytical applications by qualified research professionals.






Reviews
There are no reviews yet.